TY  - CHAP
M1  - Book, Section
TI  - Metastatic Breast Cancer
A1  - Garber, Haven R.
A1  - Karuturi, Meghan S.
A1  - Hortobagyi, Gabriel N.
A2  - Kantarjian, Hagop M.
A2  - Wolff, Robert A.
A2  - Rieber, Alyssa G.
Y1  - 2022
N1  - 
T2  - The MD Anderson Manual of Medical Oncology, 4e
AB  - KEY  CONCEPTSMetastatic  breast  cancer  (MBC)  most  commonly  arises  from  prior  early-stage  breast  cancer  and  is  incurable,  with  prognosis  influenced  by  disease  subtype  (hormone  receptor  [HR]  and  HER2  receptor  status).Treatment  of  MBC  is  increasingly  guided  by  disease  biology,  and  the  armamentarium  of  treatments  includes  several  targeted  agents,  antibodies  and  antibody-drug  conjugates,  and  checkpoint  inhibitors.Patients  can  live  many  years  with  MBC  and  preserving  quality  of  life,  minimizing  toxicity,  and  shared  patient-physician  decision  making  are  paramount  in  planning  the  best  treatment  strategy.Endocrine  therapy  remains  the  backbone  of  treatment  for  HR-positive  MBC  and  now  includes  CDK4/6  inhibitors  as  standard  frontline  treatment.The  clinical  outcomes  of  patients  with  HER2-positive  MBC  continue  to  improve  because  of  the  efficacy  of  therapies  that  target  the  HER2  kinase  pathway  including  pertuzumab,  ado-trastuzumab  emtansine,  and  tucatinib.Metastatic  triple-negative  breast  cancer  remains  the  breast  cancer  subtype  with  the  worst  prognosis.  However,  multiple  clinical  trials  are  underway  that  incorporate  immunotherapy,  antibody-drug  conjugates,  and  targeted  therapies  in  an  effort  to  improve  outcomes  over  those  achieved  with  standard  chemotherapy.  
SN  - 
PB  - McGraw Hill Education
CY  - New York, NY
Y2  - 2023/03/30
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1190836453
ER  -